ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1968

Highly activated IL-23/Th17 axis and JAK2/STAT3 signal pathway in PBMC of active AS patients involve in pathogenesis of AS

Hongxiao Liu1, Peng Chen2, Yingyan Zhou2, Junyao Song2, Benyong Liu2, Xiaoyan Feng2 and Xinghua Feng2, 1Department of Rheumatology, Guang�'anmen Hospital, China Academy of Chinese Medical Sciences, Bei Jing, China, 2Guang’anmen Hospital, China Academy of Chinese Medical Sciences, Bei Jing, China

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: IL-23 and Janus kinase (JAK)

  • Tweet
  • Email
  • Print
Session Information

Title: Cytokines, Mediators, Cell-cell Adhesion, Cell Trafficking and Angiogenesis

Session Type: Abstract Submissions (ACR)

Background/Purpose: T helper cell(Th17), the third lineage of CD4+T cells, has been determined its important role in pathogenesis of AS, and its main effector, IL-17, has a critical effect on mediating AS inflammation. Survival and function of Th17 is dependent on induction of IL-23. And JAK2/STAT3 signal pathway works on IL-23 signal transduction essentially. Here we investigate the role of JAK2/STAT3 signal pathway and IL-23/Th17 in pathogenesis of AS.

Methods: A total of 30 AS patients( average age, 27.6±9.5years) in active stage and 30 healthy controls(average age, 23.5±3.6 years) without any tissue diseases participated in the experiments. All patients were diagnosed with AS by experienced rheumatologists and met with the modified New York criteria(Bath Disease Activity Score ≥4). The serum level of IL-17 and IL-23 in peripheral serum were detected by enzyme-linked immunosorbent assay(ELISA), the percentage of Th17 were detected by flow cytometry, the protein levels of JAK2/STAT3 signal pathway mainly involved in IL-23R, JAK2, pJAK2, STAT3, pSTAT3 and RORc(the lineage-specific transcription factor of Th17) were detected by Western blotting, and the mRNA level of RORc was detected by real-time quantitative PCR(qPCR).

Results: The serum IL-23 and IL-17 levels were significantly higher of active AS patients than that of the healthy controls(IL-23:p<0.001; IL-17:p<0.001). The frequency of Th17 in PBMCs were also elevated(p<0.001). About the proteins of JAK2/STAT3 signal pathway, the level of IL-23R was higher in PBMCs of AS patients than that of the healthy controls (p<0.05), and though we found no differences of JAK2 and STAT3 in PBMCs between AS patients and healthy controls(JAK2:p=0.538; STAT3_p=0.0.554), the phosphorylated levels of JAK2 and STAT3 were critically higher(pJAK2:p<0.001; pSTAT3:p<0.001). Besides, the protein level and mRNA level of RORc were both significantly higher in PBMCs of AS patients than that of the healthy controls(protein level: p<0.001; mRNA level: p<0.001).

Conclusion: Our findings showed the exist of high serum IL-23 level, high activity degree of JAK2/STAT3 signal pathway and high protein and mRNA level of RORc in active AS patients. Important as IL-23 for Th17’s differentiation and function, STAT3 phosphorylated by IL-23 signal can not only promote the expression of RORc, acting on differentiation of Th17, but bind to IL-17’s promoter, being a direct regulator of IL-17. That’s to say, high serum IL-23 level and its active JAK2/STAT3 signal pathway play a critical role in resulting in high serum IL-17 level and high frequency of Th17 existed in active AS patients. In this way, our results suggest the possible role of JAK2/STAT3 signal pathway and IL-23/Th17 axis in pathogenesis of AS.


Disclosure:

H. Liu,
None;

P. Chen,
None;

Y. Zhou,
None;

J. Song,
None;

B. Liu,
None;

X. Feng,
None;

X. Feng,
None.

  • Tweet
  • Email
  • Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/highly-activated-il-23th17-axis-and-jak2stat3-signal-pathway-in-pbmc-of-active-as-patients-involve-in-pathogenesis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology